The amazing effects of HCG on the hypothalamus were discovered by Dr. Albert T. W. Simeons in 1954, who observed that malnourished women tend to give birth to healthy babies with normal birth weights. Dr. Simeons concluded that women are able to do this because the HCG hormone that their bodies naturally produced during pregnancy helped their bodies to metabolise subcutaneous fat. hCG released by the embryo also helps women with weight redistribution (helps prevent uneven deposits of weight on thighs, abdomen, hips etc) and therefore women concerned with hormonal weight gain are ideal candidates for this diet.
Australian owned and operated., Peptide Clinics is fully licensed and registered with our offices located in Sydney, NSW, Australia. Specialising in the production of dr approved, clinical grade peptides, Peptide Clinics Australia guarantees optimal purity and potency of their peptide supplements. Our peptide treatments each come with a Certificate of Analysis, confirming the absence of contaminants. Our online gateway grants you a secure and confidential access to buy peptide supplements online in Australia coupled with expert medical guidance in their safe and efficient use. Our licensed Dr is a renowned expert in his field of anti-ageing, longevity and sports medicine. His supervision and specialisation in peptide supplementation significantly benefit each Peptide Clinic patient in Australia.

The evidence so far suggests that there may be some effect on cartilage and bone densities, and it is correlated with weight loss. I understand that there is no evidence to suggest that it stimulates the release of IGF-1, which is the mechanism via which growth hormone gets most of its purported performance enhancing effects (i.e. muscle bulk). Whilst this is a decent list of things to test if one is considering AOD9604 as simply a variant of growth hormone, it is by no means exhaustive of all the mechanisms via which a drug can enhance athletic performance. The evidence thus far suggests that AOD9604 could be performance enhancing, but there is nothing I would hang my hat on. That is why I maintain that Dank is more sorcerer than scientist.

Thirty-two rabbits were divided into 4 equal groups. Four different solutions, including saline, HA, AOD9604, and AOD9604 with HA, were injected in each group on a weekly basis for 4–7 weeks after the first collagenase injection. Group 1 received intra-articular saline injection (0.6 mL). Group 2 received intra-articular HA, (Hyruan-plus®; LG Life Science, Daejeon, Korea) injection (6 mg). The molecular weight of HA was measured at 3.0×106 Da, and it was prepared to a 10 mg/mL concentration. Group 3 received intra-articular AOD9604 (Metabolic pharmaceuticals, Melbourne, Australia) injection (0.25 mg per 0.6 mL). Group 4 received combined intra-articular AOD9604 (0.25 mg) and HA (6 mg) injections. All injections were administered by a physiatrist, using a commercially available ultrasound system with 3–12 MHz multi-frequency linear transducer (E-CUBE 15®; Alpionion Medical Systems, Seoul, Korea) under general anesthesia and under sterile conditions (Figure 1). No medication was administered after the injection. The rabbits were euthanized by CO inhalation 9 weeks after the first collagenase injection (Figure 2).


At both visits, saline infusion was associated with a significant increase in left ventricular (LV) end‐diastolic volume (P=0.001 for saline effect), whereas LV end‐systolic volume was unchanged. Stroke volume and cardiac output increased in response to saline administration at both pre‐ and post‐bypass visits. The effect of saline infusion on cardiac function did not differ before and after surgery (saline×surgery interaction P values non‐significant).
The first was a double-blind, placebo-controlled, parallel group, multi-center study (5 Australian hospitals) (METAOD005). In this study 300 healthy obese males and females (BMI ≥ 35 kg/m2; Median BMI: 40 kg/m2, range: 35 to 67 kg/m2; 30 to 65 years old; 54% males and 46% females) were randomized to a 14-week period of daily oral dosing. The treatment period comprised a 2-week single-blind placebo run-in period followed by 12 weeks administration of either placebo or AOD9604 (1, 5, 10, 20 or 30 mg AOD9604 or placebo once daily; n =50 per group).
Thirty-two rabbits were divided into 4 equal groups. Four different solutions, including saline, HA, AOD9604, and AOD9604 with HA, were injected in each group on a weekly basis for 4–7 weeks after the first collagenase injection. Group 1 received intra-articular saline injection (0.6 mL). Group 2 received intra-articular HA, (Hyruan-plus®; LG Life Science, Daejeon, Korea) injection (6 mg). The molecular weight of HA was measured at 3.0×106 Da, and it was prepared to a 10 mg/mL concentration. Group 3 received intra-articular AOD9604 (Metabolic pharmaceuticals, Melbourne, Australia) injection (0.25 mg per 0.6 mL). Group 4 received combined intra-articular AOD9604 (0.25 mg) and HA (6 mg) injections. All injections were administered by a physiatrist, using a commercially available ultrasound system with 3–12 MHz multi-frequency linear transducer (E-CUBE 15®; Alpionion Medical Systems, Seoul, Korea) under general anesthesia and under sterile conditions (Figure 1). No medication was administered after the injection. The rabbits were euthanized by CO inhalation 9 weeks after the first collagenase injection (Figure 2).

When you buy peptides online through Peptide Clinics you can be ensured of our commitment to your success. Peptide Clinics specialises in supplying premium peptide supplements, incorporated into custom treatment programs to assist you in meeting your health and fitness goals. All new client questionnaires are screened by one of our highly trained and experienced medical doctors. All initial and follow-up blood tests are also screened by our doctors, who use this information to recommend the peptide best suited for you, with its dose and frequency. Programs are customised on a per client basis dependent on your goals and blood test results, which are regularly reviewed and modified to ensure optimal peptide performance.
I’m 50 and have been using CJC-1295+Ipamorelin Combo for almost 1 year now. Yes with 2 rest periods. Very very happy with the results. Skin is smoother / softer to touch reduced bags under my eyes, my wife loves the new feel. I train 5 days a week and the increase in muscle volume and tone is very noticeable. I will say however it is a slow steady natural looking increase. Recovery is great and I think it is helping with injury repair, as i have a problem Knee that is feeling alot better ever since I’ve been on this product. As you can see the cost is high but if there were no outstanding results my wife would say I was a Di#*head, but she is encouraging me to continue. Train hard, eat well and look better. Use CJC-1295+Ipamorelin Combo. I do
Growth Hormone (GH) and IGF-1 are naturally occurring hormones in the human body responsible for many enviable aesthetic traits such as muscle mass, leanness and a firm/even skin tone. As people age, levels of growth hormone rapidly decline and this is one of the main reasons humans put on weight, lose muscle mass and develop sagging/uneven skin. It's no surprise then that synthetic Human Growth Hormone is a sought after product for anti-aging by persons looking to remain youthful, bodybuilders looking to put on muscle mass and people in general who are looking to "tone up" or lose stubborn belly fat.
Although growth hormone and growth hormone releasing hormones are classified as prescription drugs, there is a safe and legal way to increase your levels of hGH production. There are a range of growth hormone supplements designed to boost hGH production within normal limits. For more information, please refer to our “Natural Growth Hormone Supplements Guide”.
Prior to commencement of active treatment, 48.4% of subjects experienced at least one AE. The body system organ classes with the highest incidences of events (> 10%) were the nervous system (17.5%; mainly headache, 14.5%), infections and infestations (15.9%, mainly nasopharyngitis and upper respiratory tract infection, 4.0%), gastrointestinal system (12.4%, mainly diarrhea 3.2%) and musco-skeletal and connective tissue disorders (12.0%, mainly back pain, 4.0%), 32.9% of subjects experienced mild AEs, 38.6% experienced moderate AEs and 36 (7.2%) patients experienced severe AEs. The intensity of AEs was similar across all treatment groups. None of the AEs were deemed to be definitely related to the study treatment.
In plasma, different isoforms and fragments of hGH were found [10]. Research on specific domains and fractions of the protein revealed that they can be assigned to different actions of the protein: In vitro and in vivo experiments have shown that several fragments of the amino terminal region of hGH, namely 1-15, 1-42, 6-13, and 32-46, exhibit an insulin-potentiating action [14-16]. The region hGH 108-129 was found to evoke high mitogenic responses [17], while the carboxy terminus hGH177-191 seemed to be a lipid mobilizing domain, inhibiting the acetyl-CoA carboxylase activity in adipocytes and hepatocytes [18].
Despite the controversies, some scientists continued with additional studies and again proved IGF-1 to actually prolong life…at least in worms.  Then, in 2001, scientists discovered that the use of IGF-1 resulted in a proliferation of cancer cells, especially throughout the breast and colon, and a 2012 study found that both too much or too little IGF-1 could contribute to dying from cancer; implying that IGF-1 actually helped patients with terminal cancer live longer.
Strengths of our study include the serial physiologic assessments before and after bariatric surgery. The gastric bypass procedure ensured a large degree of weight loss (≈27% mean change in BMI), while the administration of normal saline provided an acute stimulus for eliciting acute natriuretic peptide responses. Thus, we were able to compare the relative effects of weight loss and saline infusion, with each individual serving as his or her own control. This study design minimizes confounding from sources of natriuretic peptide variation that might correlate with BMI. We performed the post‐surgical assessment 6 months after surgery to ensure that acute hemodynamic changes from surgery had resolved and patients had attained most of their expected weight loss. Mitral annular early diastolic (e′) velocity at the lateral annulus has been accepted as an index of diastolic function24, 25 and we had significant improvement in e′ suggesting improvement in myocardial relaxation. Our echocardiographic findings are in accordance with the recently published meta‐analysis demonstrating benefits of bariatric surgery on diastolic function.26
The other submission commented on the consideration to place AOD-9604 in Appendix D. The submission supported listing in Schedule 4, but raised concerns that listing the substance in Appendix D would limit any future development work, including clinical trials that are currently being conducted on the substance. The submitter notes that there are currently 5 clinical trials notified to the TGA using this substance , with these approved clinical trials going ahead on the basis that the substance is safe for human use. Inclusion in Appendix D may place unnecessary burden on those conducting these clinical trials.
Background: The human growth hormone (hGH) has properties making it a potential candidate to treat obesity, however safety issues limit its long-term use. AOD9604 is a peptide fragment of the C-terminus of hGH (Tyr-hGH177-191), which harbors the fat reducing activity of hGH, without its negative effects. In this paper the safety data of AOD9604 obtained in clinical trials are summarized.
Monash University discovered that the fat-reducing effects of GH appear to be controlled by a small region near one end of the GH molecule. This region, which consists of amino acids 176-191, is less than 10% of the total size of the GH molecule and appears to have no effect on growth or insulin resistance. It works by mimicking the way natural Growth Hormone regulates fat metabolism but without the adverse effects on blood sugar or growth that is seen with unmodified Growth Hormone. Like Growth Hormone, AOD 9604 stimulates lipolysis (the breakdown or destruction of fat) and inhibits lipogenesis (the transformation of nonfat food materials into body fat) both in laboratory testing and in animals and humans. Recent findings have shown, in addition to its fat loss properties, AOD 9604 processes many other regenerative properties associated with growth hormone. Currently trials are underway to show the application of AOD 9604 in osteoarthritis, hypercholesterolemia, bone and cartilage repair. AOD 9604 has an excellent safety profile, recently obtaining Human GRAS status in the USA.
Conclusions: Subcutaneous administration of CJC 1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 ug/ kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC 1295 as a therapeutic agent.
But gene-therapy experiments have also resulted in patient deaths. The use of such therapies can cause the human body to experience fatal immune reactions to the vectors used to place the gene in the body. Another danger of gene therapy is an inability to control the expression of the gene, which could translate into a rapidly spreading cancer. Or the expression of the gene could spread from skeletal muscle into heart muscle, resulting in excessive heart muscle growth (known as left ventricular hypertrophy, or “athlete’s heart) that can cause premature heart failure.
The prescription form of IGF-1 most often injected is “mecasermin”, which goes by the trade name Increlex. Manufactured using recombinant DNA technology, mecasermin is clinically used to treat IGF-1 deficiency and stunted growth. It is also prescribed to patients who have developed antibody resistance to normal growth hormone therapy. Increlex is actually identical to natural IGF-1, meaning that it has the identical 70 amino acid sequence of IGF-1 that the body produces. In other words, it’s not some kind of growth hormone “precursor”. It’s just straight up IGF-1.
One more way for growth hormone to help with fat loss is that this sustains the levels of blood glucose through inhibiting glucose uptake to the peripheral cells, reducing the glucose oxidation for the energy in cells and thus boosting the production of the glucose in the cells from amino acids and fats. The blood’s free fatty acids from lipolysis also partially obstruct the insulin receptors on the cell membranes, reducing insulin’s effectiveness in triggering glucose removal from the blood that causes decreased sensitivity to insulin or insulin resistance. These will then result to fat loss, particularly from the difficult to move intra-abdominal storages of fat.
Time line of collagenase, saline, HA and AOD9604 injection. Collagenase (0.25 mg) was injected in right knee twice on day 1 and 4, respectively. Normal saline 0.6 ml (group 1), HA 6 mg (group 2), AOD9604 0.25 mg (group 3), and AOD9604 0.25mg with HA 6 mg (group 4) were injected in the right knee at 4 weeks after the first collagenase injection. All rabbits were euthanized by CO inhalation at 4 weeks after injection of 4 different solutions.
The most common goal of people in the health and fitness world is to lose weight. Not only do hundreds of millions of people go on diets to try and lose weight every year, but they want to lose weight as fast as possible. It’s no wonder the weight loss industry is a $20 billion industry, with the sales of books, diet drugs, and weight-loss surgeries fueling revenue as people try and lose unwanted weight once and for all.
Example 1 - Night Time Injection (recommended) ◦Ensure you do not eat or drink anything containing calories within three (3) hours of going to bed (with the exception of water, diet sodas, coffee/tea with artificial sweeteners). ◦Take your HGH Frag 176-191 injection just before getting into bed and your body will therefore be burning stored fat for the duration of your sleep. ◦If possible, do some cardio first thing in the morning and wait as long as possible before having breakfast to allow the fat burning to continue throughout the morning/day.

Both human GH (hGH) and a lipolytic fragment (AOD9604) synthesized from its C-terminus are capable of inducing weight loss and increasing lipolytic sensitivity following long-term treatment in mice. One mechanism by which this may occur is through an interaction with the beta-adrenergic pathway, particularly with the beta(3)-adrenergic receptors (beta(3)-AR). Here we describe how hGH and AOD9604 can reduce body weight and body fat in obese mice following 14 d of chronic ip administration. These results correlate with increases in the level of expression of beta(3)-AR RNA, the major lipolytic receptor found in fat cells. Importantly, both hGH and AOD9604 are capable of increasing the repressed levels of beta(3)-AR RNA in obese mice to levels comparable with those in lean mice. The importance of beta(3)-AR was verified when long-term treatment with hGH and AOD9604 in beta(3)-AR knock-out mice failed to produce the change in body weight and increase in lipolysis that was observed in wild-type control mice. However, in an acute experiment, AOD9604 was capable of increasing energy expenditure and fat oxidation in the beta(3)-AR knock-out mice. In conclusion, this study demonstrates that the lipolytic actions of both hGH and AOD9604 are not mediated directly through the beta(3)-AR although both compounds increase beta(3)-AR expression, which may subsequently contribute to enhanced lipolytic sensitivity.

GHRP + GHRH (twice per day) ◦Inject your GHRP + GHRH peptides together in the same syringe (ensuring you have not consumed any food/beverages for at least 1 hour before, an optimal time would be first thing in the morning). ◦Ingest a protein only or protein and carbohydrate meal afterward to create an insulin spike. ◦Do weight training in the hours afterwards. ◦at least 1 hour after your dinner (or last meal of the day), take your second GHRP + GHRH injection. ◦If you are trying to control your body fat then have a protein only meal 20-30 minutes afterwards, otherwise a protein/carbohydrate meal will create a better insulin spike.
Even, if you are not a fitness enthusiast, you can benefit from using the CJC 1295 Ipamorelin blend. Australia is one of the countries using them to deal with other conditions, which can affect our everyday life. There is an abundance of anti-aging clinics across the Australia that follows strict legal guidelines to sell peptides. Based in Sydney Peptides Clinics, has a good selection of peptides, to help with many conditions that occur with age, from hair loss, depression, fat loss, low libido and tanning.
Note: If you are a person concerned about loss of muscle mass, you can consume a small amount of protein every 2-3 hours (amino acid tablets such as EAA and BCAA are good for this purpose and can be purchased from any health food shop or ordered online). However there is little reason to be concerned about muscle loss because when fat is available for energy, such as following HGH Frag 176-191 injections, protein and therefore muscle mass are spared.
AOD9604 and hGH appear to act in a similar manner to induce their effects on body weight regulation and adipose tissue mass in vivo. However, in vitro studies have demonstrated a number of differences suggesting that the two compounds operate via unique signaling pathways to control the regulation of theβ 3-AR. These studies suggested that AOD9604 had no interaction with the β3-AR or hGH receptors (11).
Application would result in all current OTC paracetamol/ phenylephrine products being up-scheduled to S3. Applicant’s justification for changing current combination products from exempt or S2 to S3 is on theoretical basis only, and no evidence provided of clinical risk. Pharmacokinetic study found that co-administration of paracetamol with phenylephrine increased plasma phenylephrine levels - applicant says this has potential for cardiac safety risk in susceptible patients.
These “protein chains”, are not just turned to by gym junkies for their muscle synthesising and fat burning properties. With peptides for injury recovery and repair, cognition, anti-aging, sleep, tanning, improving libido, or anxiety, to name a few, this growing market caters for everyone. Unfortunately, there has been a lot of stigma in the public eye due to media and press, shaming their use and clouding potential in debilitating chronic conditions such as obesity, muscle atrophy, osteoarthritis, dementia, Alzheimer’s or even recovery post stroke.
×